194 related articles for article (PubMed ID: 34929598)
1. Utilizing the circulating tumor markers in diagnosis and management of medullary thyroid cancer.
Zarkesh M; Arab N; Tavangar SM; Nozhat Z; Fanaei SM; Hedayati M
Pathol Res Pract; 2022 Jan; 229():153694. PubMed ID: 34929598
[TBL] [Abstract][Full Text] [Related]
2. Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature.
Trimboli P; Giovanella L
Clin Chem Lab Med; 2015 Sep; 53(10):1507-14. PubMed ID: 25781697
[TBL] [Abstract][Full Text] [Related]
3. [Medullary thyroid carcinoma].
Tiedje V; Ting S; Dralle H; Schmid KW; Führer D
Internist (Berl); 2015 Sep; 56(9):1019-31. PubMed ID: 26338063
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen.
Woliński K; Kaznowski J; Klimowicz A; Maciejewski A; Łapińska-Cwojdzińska D; Gurgul E; Car AD; Fichna M; Gut P; Gryczyńska M; Ruchała M
Endokrynol Pol; 2017; 68(4):434-437. PubMed ID: 28585679
[TBL] [Abstract][Full Text] [Related]
5. T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T.
Erickson TA; Shih YP; Fass J; Jang M; Tran E
Thyroid; 2022 Jul; 32(7):789-798. PubMed ID: 35587601
[No Abstract] [Full Text] [Related]
6. [Application of serum markers in medullary thyroid carcinoma].
Han XD; Lu RQ; Hu HY; Guo L
Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Dec; 55(12):1468-1474. PubMed ID: 34963245
[No Abstract] [Full Text] [Related]
7. Procalcitonin for detecting medullary thyroid carcinoma: a systematic review.
Trimboli P; Seregni E; Treglia G; Alevizaki M; Giovanella L
Endocr Relat Cancer; 2015 Jun; 22(3):R157-64. PubMed ID: 25934688
[TBL] [Abstract][Full Text] [Related]
8. Clinical challenges with calcitonin-negative medullary thyroid carcinoma.
Samà MT; Rossetto Giaccherino R; Gallo M; Felicetti F; Maletta F; Bonelli N; Piovesan A; Palestini N; Ghigo E; Arvat E
J Cancer Res Clin Oncol; 2016 Sep; 142(9):2023-9. PubMed ID: 27125958
[TBL] [Abstract][Full Text] [Related]
9. Medullary Thyroid Carcinoma--Circulating Status of Vaspin and Retinol Binding Protein-4 in Iranian Patients.
Jabbari S; Hedayati M; Yaghmaei P; Parivar K
Asian Pac J Cancer Prev; 2015; 16(15):6507-12. PubMed ID: 26434866
[TBL] [Abstract][Full Text] [Related]
10. Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules.
Verbeek HH; de Groot JWB; Sluiter WJ; Muller Kobold AC; van den Heuvel ER; Plukker JT; Links TP
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD010159. PubMed ID: 32176812
[TBL] [Abstract][Full Text] [Related]
11. Circulating pro-gastrin releasing peptide (ProGRP) in patients with medullary thyroid carcinoma.
Giovanella L; Fontana M; Keller F; Campenni' A; Ceriani L; Paone G
Clin Chem Lab Med; 2021 Aug; 59(9):1569-1573. PubMed ID: 33860650
[TBL] [Abstract][Full Text] [Related]
12. Medullary Thyroid Carcinoma: Prognostic Variables And Tumour Markers Affecting Survival.
Hassan A; Siddique M; Riaz S; Khan AI; Nawaz MK; Bashir H
J Ayub Med Coll Abbottabad; 2018; 30(Suppl 1)(4):S627-S632. PubMed ID: 30838820
[TBL] [Abstract][Full Text] [Related]
13. Utility of proGRP as a tumor marker in the medullary thyroid carcinoma.
Parra-Robert M; Orois A; Augé JM; Halperin I; Filella X; Molina R
Clin Chem Lab Med; 2017 Mar; 55(3):441-446. PubMed ID: 27754959
[TBL] [Abstract][Full Text] [Related]
14. Basal and pentagastrin-stimulated calcitonin cut-off values in diagnosis of preoperative medullary thyroid cancer.
Kartal Baykan E; Erdoğan M
Turk J Med Sci; 2021 Apr; 51(2):650-656. PubMed ID: 33128357
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.
Maia AL; Siqueira DR; Kulcsar MA; Tincani AJ; Mazeto GM; Maciel LM
Arq Bras Endocrinol Metabol; 2014 Oct; 58(7):667-700. PubMed ID: 25372577
[TBL] [Abstract][Full Text] [Related]
16. Carcinoembryonic antigen levels correlated with advanced disease in medullary thyroid cancer.
Turkdogan S; Forest VI; Hier MP; Tamilia M; Florea A; Payne RJ
J Otolaryngol Head Neck Surg; 2018 Sep; 47(1):55. PubMed ID: 30223887
[TBL] [Abstract][Full Text] [Related]
17. Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients.
Romeo P; Colombo C; Granata R; Calareso G; Gualeni AV; Dugo M; De Cecco L; Rizzetti MG; Zanframundo A; Aiello A; Carcangiu ML; Gloghini A; Ferrero S; Licitra L; Greco A; Fugazzola L; Locati LD; Borrello MG
Endocr Relat Cancer; 2018 Mar; 25(3):217-231. PubMed ID: 29298817
[TBL] [Abstract][Full Text] [Related]
18. Medullary thyroid cancer outcomes in patients with undetectable versus normalized postoperative calcitonin levels.
Fanget F; Demarchi MS; Maillard L; Lintis A; Decaussin M; Lifante JC
Br J Surg; 2021 Sep; 108(9):1064-1071. PubMed ID: 33899100
[TBL] [Abstract][Full Text] [Related]
19. Multiple Endocrine Neoplasia Type 2B Associated Mixed Medullary and Follicular Thyroid Carcinoma in A Chinese Patient with RET M918T Germline Mutation.
Qi XP; Lin GB; Chen B; Li F; Cao ZL; Zheng WH; Zhao JQ
Endocr Metab Immune Disord Drug Targets; 2021; 21(3):554-560. PubMed ID: 32660411
[TBL] [Abstract][Full Text] [Related]
20. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND
Yang JH; Camacho CP; Lindsey SC; Valente FOF; Andreoni DM; Yamaga LY; Wagner J; Biscolla RPM; Maciel RMB
Endocr Pract; 2017 Aug; 23(8):942-948. PubMed ID: 28614009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
